Dr Richard Lipscombe, Managing Director of Proteomics International (ASX:PIQ), spoke with 2GB’s...
New Oesophageal Cancer Diagnostic shows strong performance
The Company is pleased to announce its prototype diagnostic test for oesophageal adenocarcinoma has shown strong diagnostic performance detecting up to 90% of people with the frequently fatal condition. The results were presented overnight at the 18th World Congress for Esophageal Diseases being held virtually, and in Tokyo, Japan 26-28 September 2022.
The Oesophageal Cancer Diagnostic is Proteomics International’s latest test from the Company’s Promarker™ Pipeline. The results build on a successful collaboration with the QIMR Berghofer Medical Research Institute [ASX: 4 February 2022] which validated a select panel of biomarkers in a study of more than 300 patients across two independent clinical cohorts. Proteomics International owns the exclusive worldwide rights to commercialise the biomarkers, which are patented in multiple jurisdictions [ASX: 21 June 2022].